We have previously shown that p-AKT expression is low in AZD6244-sensitive lung cancer cell lines but high in resistant cells, suggesting that p-AKT is a potential biomarker of sensitivity to AZD6244 treatment. Here, AKT1 is linked to lung carcinoma.